LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

Adaptive Biotechnologies Corp

Closed

13 0.62

Overview

Share price change

24h

Current

Min

12.95

Max

13.06

Key metrics

By Trading Economics

Income

4.2M

-26M

Sales

6.4M

59M

Profit margin

-43.467

Employees

619

EBITDA

11M

-18M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+5.44% upside

Dividends

By Dow Jones

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

193M

1.9B

Previous open

12.38

Previous close

13

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

Adaptive Biotechnologies Corp Chart

Past performance is not a reliable indicator of future results.

Related News

15 Aug 2025, 16:11 UTC

Major Market Movers

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

15 Aug 2025, 22:22 UTC

Market Talk

Global Equities Roundup: Market Talk

15 Aug 2025, 22:22 UTC

Market Talk

Target Is Falling Behind Its Peers -- Market Talk

15 Aug 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 Aug 2025, 20:33 UTC

Market Talk

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

15 Aug 2025, 20:25 UTC

Earnings
Acquisitions, Mergers, Takeovers

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

15 Aug 2025, 20:24 UTC

Earnings
Acquisitions, Mergers, Takeovers

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15 Aug 2025, 20:18 UTC

Earnings

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15 Aug 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

15 Aug 2025, 19:12 UTC

Market Talk

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

15 Aug 2025, 18:32 UTC

Market Talk

Coffee Futures Surge on New Brazilian Frost -- Market Talk

15 Aug 2025, 17:33 UTC

Market Talk

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

15 Aug 2025, 17:23 UTC

Market Talk
Earnings

Deere's Earnings Appear to Be Troughing -- Market Talk

15 Aug 2025, 16:27 UTC

Earnings

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

15 Aug 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 Aug 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15 Aug 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15 Aug 2025, 16:05 UTC

Acquisitions, Mergers, Takeovers

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

15 Aug 2025, 15:52 UTC

Acquisitions, Mergers, Takeovers

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

15 Aug 2025, 15:36 UTC

Market Talk

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

15 Aug 2025, 15:29 UTC

Earnings

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15 Aug 2025, 15:29 UTC

Acquisitions, Mergers, Takeovers

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15 Aug 2025, 15:28 UTC

Earnings

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

15 Aug 2025, 15:24 UTC

Market Talk

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

15 Aug 2025, 15:08 UTC

Market Talk

Applied Materials Is Losing Share in Chips Business -- Market Talk

15 Aug 2025, 14:38 UTC

Acquisitions, Mergers, Takeovers

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

15 Aug 2025, 14:37 UTC

Acquisitions, Mergers, Takeovers

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

15 Aug 2025, 14:37 UTC

Acquisitions, Mergers, Takeovers

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

15 Aug 2025, 14:36 UTC

Acquisitions, Mergers, Takeovers

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

15 Aug 2025, 14:33 UTC

Acquisitions, Mergers, Takeovers

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Peer Comparison

Price change

Adaptive Biotechnologies Corp Forecast

Price Target

By TipRanks

5.44% upside

12 Months Forecast

Average 13.75 USD  5.44%

High 15 USD

Low 11 USD

Based on 8 Wall Street analysts offering 12 month price targets forAdaptive Biotechnologies Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

6

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

8.81 / 10.18Support & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.